TNFSF10 and neoplasm: Apo2L/TRAIL was demonstrated safe and nonimmunogenic (Ashkenazi et al, 1999; Walczak et al, 1999), was active alone in some cancer types (Ashkenazi et al, 1999) and exhibited synergistic activity with chemotherapeutic agents, causing marked regression or complete remission of tumours (Ashkenazi et al, 1999; Walczak et al, 1999).